跳至主要内容
临床试验/NCT02508558
NCT02508558Unknown不适用

Validation of Methods for Evaluating Operation Force, Motion and Visual Perception in Weightlessness

University Hospital, Caen1 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2014年9月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
入组人数
18
试验地点
1
主要终点
motion perception performance under different gravity states

研究概览

简要总结

Previous studies have neglected two important aspects for the China National Space Administration. First, while biomechanical models are very sensitive to the characteristics of the subjects, data have been collected on subjects with biomechanical characteristics very different from those of "typical" Chinese astronauts. Second, pure video analysis techniques and kinematic data lack the necessary acceleration information important to understanding the forces exerted during movement and control of human motion. While some studies used force and moment sensors to aid in robot torque control and human joint work estimation, investigators are unaware of any studies performed in a microgravity environment that have combined the kinetic force and moment information with acceleration measurements to enable more reliable motion tracking without the need for acceleration estimation.

This is why MICR0-G sensors and accompanying kinematic video system have been developed in order to provide for detailed analyses of the astronaut movement control strategy (joint forces and torques, kinetic and acceleration measurements). Knowledge of the joint torques permits us to calculate the joint and musculoskeletal dynamics required to execute the microgravity motions, as well to provide insight into the altered movement strategies in reduced gravity as compared to 1-G locomotion.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
22 Years 至 45 Years(Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Healthy Chinese volunteers (men or women)
  • •Living in France and affiliated to a French Social Security system
  • •Aged from 22 to 45
  • •Body Mass Index from 19 to 25
  • •Who accepted to take part in the study
  • •Who has given their written stated consent
  • •Who has passed a medical examination similar to a standard aviation medical examination for private pilot aptitude (JAR FCL3 Class 2 medical examination). There will be no additional test performed for subject selection

排除标准

  • •Person who took part in a previous biomedical research protocol, of which exclusion period is not terminated
  • •Pregnant women

研究组 & 干预措施

Measurements under different gravity states

Other

motion perception and locomotor operation performance under different gravity states

干预措施: motion perception and locomotor operation performance measurements (Other)

Measurements under different gravity states

Other

motion perception and locomotor operation performance under different gravity states

干预措施: parabolic flight (Other)

结局指标

主要结局

motion perception performance under different gravity states

时间窗: baseline

MICR0-G sensors and accompanying kinematic video system analyses of the astronaut movement control strategy (joint forces and torques, kinetic and acceleration measurements).

locomotor operation performance under different gravity states

时间窗: baseline

MICR0-G sensors and accompanying kinematic video system analyses of the astronaut movement control strategy (joint forces and torques, kinetic and acceleration measurements).

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

进行中(未招募)
不适用
Ensayo de fase II para evaluar la eficacia y la seguridad de panitumumab combinado con docetaxel y cisplatino como tratamiento de primera línea del adenocarcinoma gástrico o de la unión gastroesofágica en estadio avanzado - SPIGAEnsayo fase II para evaluar la eficacia y seguridad de panitumumab combinado con docetaxel y cisplatino como tratamiento de primera línea del adenocarcinoma gástrico o de la unión gastroesofágica en estado avanzado.
EUCTR2010-021192-87-ESGrupo Gallego de Investigación en Oncología - GGIO
进行中(未招募)
不适用
Etude de phase II nationale multicentrique évaluant l’activité antitumorale du sunitinib (SUTENT) chez des patients atteints d’hépatocarcinomes fibrolamellaires inopérables d’emblée ou en rechute non opérable, couplée à une identification de biomarqueurs prédictifs de réponse au sunitinib. - FIBROLAMELLAIREpatients atteints d'hépatocarcinome fibrolamellaire non opérable ou en échec du traitement chiruirgicalMedDRA version: 8.1Level: PTClassification code 10019838Term: carcinome hépatocellulaire fibrolamellaire
EUCTR2008-003423-23-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
进行中(未招募)
不适用
ESTUDIO FASE II PARA VALORAR LA EFICACIA Y SEGURIDAD DEL RECAMBIO PLASMÁTICO CON ALBÚMINA 5% EN EL ACLARAMIENTO DEL PÉPTIDO BETA-AMILOIDE EN LÍQUIDO CEFALORRAQUÍDEO, Y SUS EFECTOS EN PACIENTES CON ENFERMEDAD DE ALZHEIMER LEVE-MODERADAEnfermedad de Alzheimer, leve a moderada
EUCTR2007-000414-36-ESInstituto Grifols, S.A.
进行中(未招募)
1 期
EVALUATION OF THE EFFICIENCY AND TOLERANCE OH THE CHIMIOTHERAPY REGORAFENIB IN 70 YEARS OLD AND MORE PATIENTS WITH A METASTATIC COLORECTAL CANCERMedDRA version: 18.0Level: PTClassification code 10061451Term: Colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2015-002086-29-FRFEDERATION FRANCOPHONE DE CANCEROLOGIE DIGESTIVE42
进行中(未招募)
1 期
Estudio de fase II para evaluar la eficacia y la seguridad de la quimiorradioterapia con 5-fluorouracilo, mitomicina C y panitumumab como tratamiento del carcinoma anal de células escamosasTratamiento de primera línea para pacientes con cáncer de células escamosas del canal anal locorregional
EUCTR2010-018430-48-ESGrupo Español Multidisciplinar en cáncer Digestivo-GEMCAD